Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 15, 2014
Make sterile connections faster, easier and safer with genderless connectors
Simplify single-use systems with AseptiQuik? genderless connectors from CPC. Innovative design eliminates separate male and female components to reduce system complexity and inventory requirements, while increasing process flexibility
Advertisement
Make sterile connections faster, easier and safer with genderless connectors
Genderless AseptiQuik® G sterile connectors from CPC simplify single-use systems design and process integration. Our innovative design eliminates separate male and female components to substantially reduce complexity and support modular system design. Because the connectors are interchangeable—any single-use G series connector mates with any other G series connector-systems are more flexible and minimize supply chain complexity.
G series connectors are available in a full range of interchangeable 6.4 mm to 19.0 mm (1/4” to 3/4”) flow solutions, in both gamma and high-temperature versions. Terminations include 6.4 mm to 19.0 mm hose barb and 19.0 mm mini-sanitary.
The G series is part of the AseptiQuik family which offers the broadest range of single-use sterile connectors in the industry with flow configurations from 3.2 mm to 25.4 mm (1/8” to 1”). AseptiQuik connectors provide ease-of-use, robust construction and reliable performance for transferring valuable media. AseptiQuik’s are ideal for single-bag and tubing assemblies,cell banking, bioreactors, mixers,
sampling, formulation and filling applications.
See how the G series works
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement